Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UNC to test new assist device for failed livers

12.03.2003




Prospects for surviving acute liver failure are very slim, and statistics place mortality as high as 90 percent. A liver transplant may be the only alternative before fatal complications set in, yet not enough donor organs are available to meet the demand.

But a new bio-artificial technology about to undergo clinical tests at the University of North Carolina at Chapel Hill and several other centers nationally may help extend the lives of those awaiting a donor liver and may even allow the damaged liver to heal itself completely.

Known by its acronym ELAD, the extracorporeal liver assist device is the first such technology to contain functioning human hepatocytes, liver cells that help sustain and support the work of the patient’s damaged and failed organ. Other liver assist systems use hepatocytes from pigs.



The new device is a closed system to which patients are tethered via a catheter inserted into a vein in the neck. After the blood is initially filtered, the remaining plasma goes through cartridges in the ELAD where the human hepatocytes help fulfill much of the liver’s 100 or so crucial functions, such as energy storage and regulation, bile production, blood detoxification, production of clotting factors and many essential proteins. The filtered blood and ELAD-treated plasma are returned to the patient.

Dr. Roshan Shrestha, associate professor of medicine and medical director of the liver transplantation program at UNC, said ELAD could provide two major benefits.

"This device could serve as a bridge to successful transplantation, helping to sustain patients awaiting a donor organ."

It also may enable complete recovery, he added.

"A remarkable feature of the liver is its capacity to regenerate. If we can sustain acute liver failure patients early on, right from the beginning, they may not need transplantation and may recover without any significant liver problems, including chronic liver disease."

Shrestha, principal investigator for the UNC study site, said a first-phase clinical trial conducted in the United States and Great Britain during 1999 and 2000 showed promising results. In that study, sponsored by ELAD maker Vitagen Inc., 11 of 12 (91.6 percent) of patients who had been randomized to receive treatment with the new device achieved either a successful bridge to transplantation or full recovery. In a control group of patients receiving standard care, three of seven (42 percent) achieved those benefits.

In an analysis of overall results in 25 patients, including those not listed for liver transplantation, 13 of 16 (81 percent) improved on the device, compared to only five of nine (51 percent) in the control group.

Shrestha said the U.S. Food and Drug Administration was sufficiently pleased with the results to give its nod to a second-phase trial, also sponsored by Vitagen. Safety and effectiveness, including survival at 30 days, is the main endpoint, Shrestha said.

"The primary objective is to evaluate the safety, efficacy and tolerability of the ELAD system in patients with acute hepatic [liver] failure. Our secondary objective is to evaluate the study protocol with respect to patient inclusion and exclusion criteria and to study the system’s performance with regard to endpoints." Total enrollment for this trial is between 30 and 40 patients. A larger third-phase trial may follow, with an enrollment of at least 200 people with acute liver failure.

"Currently, we don’t have very good therapies for patients with acute liver failure. That’s why we’re hoping that the new technology will make a big difference," Shrestha said. "The bottom line is to save lives."


Note: Contact Shrestha at (919) 843-9459 or (919) 966-2516 (choose option "O"), or r_shrestha@med.unc.edu.

School of Medicine contact: Les Lang, (919) 843-9687 or llang@med.unc.edu


Leslie H. Lang | EurekAlert!
Further information:
http://www.med.unc.edu/

More articles from Health and Medicine:

nachricht The end of pneumonia? New vaccine offers hope
23.10.2017 | University at Buffalo

nachricht Scientists track ovarian cancers to site of origin: Fallopian tubes
23.10.2017 | Johns Hopkins Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Shrews shrink in winter and regrow in spring

24.10.2017 | Life Sciences

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>